Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production

US9833454B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Kenneth M. Boy · Durham, US
• Stephen E. Mercer · Wilmington, US
• Richard E. Olson · Wilmington, US
• Xiaoliang Zhou · Nantong, CN

Key dates

• Filing date: Apr 1, 2015
• Grant date: Dec 5, 2017
• Expiry date: Apr 1, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2121/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.